Long-term response to vasoactive treatment in a case of kyphoscoliosis-associated pulmonary hypertension

Simple item page
dc.contributor.authorTellermann, Jonas
dc.contributor.authorSablinskis, Matiss
dc.contributor.authorMachado, Patricia Raquel Ribeiro
dc.contributor.authorSablinskis, Kristaps
dc.contributor.authorSkride, Andris
dc.contributor.institutionRīga Stradiņš University
dc.date.accessioned2021-07-15T08:15:01Z
dc.date.available2021-07-15T08:15:01Z
dc.date.issued2019
dc.descriptionPublisher Copyright: © Am J Case Rep, 2019.
dc.description.abstractObjective: Unusual setting of medical care Background: Kyphoscoliosis is an anatomical deformity of the spine often accompanied by an array of respiratory complications, pulmonary hypertension being among the most severe ones. At present, evidence-based treatment options for kyphoscoliosis-related pulmonary hypertension remain limited to the correction of hypoxemia through ventilatory support and long-term oxygenation. Case Report: We report a case of a 61-year-old female with severe kyphoscoliosis-related pulmonary hypertension who was admitted to a university hospital in September 2018 due to progressive dyspnea and respiratory failure. She was diagnosed with pulmonary hypertension in 2016 and had been on endothelin receptor antagonist (ambrisentan) and oxygen therapy ever since. Upon admission, the patient presented with severe depression of peripheral oxygen saturation (SpO2 at 75%). The patient declined further treatment hours after hospitalization, despite optimized supportive oxygen therapy. Ambrisentan was discontinued and replaced by inhaled iloprost. Over the course of the next 4 days, the patient showed symptomatic improvement and was discharged on Day 5. Right heart catheterization follow-up in February 2019 showed no worsening in pulmonary hemodynamic parameters compared to the time of initial diagnosis. Conclusions: Managing the respiratory decline in kyphoscoliosis-related pulmonary hypertension can be challenging since these patients tend to deteriorate despite current treatment options. Our case reports on the use of vasoactive agents as a safe and effective treatment option in addition to established therapeutic regimen.en
dc.description.statusPeer reviewed
dc.format.extent4
dc.format.extent1195925
dc.identifier.citationTellermann, J, Sablinskis, M, Machado, P R R, Sablinskis, K & Skride, A 2019, 'Long-term response to vasoactive treatment in a case of kyphoscoliosis-associated pulmonary hypertension', American Journal of Case Reports, vol. 20, pp. 1505-1508. https://doi.org/10.12659/AJCR.917154
dc.identifier.doi10.12659/AJCR.917154
dc.identifier.issn1941-5923
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/5885
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85073165337&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofAmerican Journal of Case Reports
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHypertension, Pulmonary
dc.subjectKyphosis
dc.subjectScoliosis
dc.subject3.2 Clinical medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectGeneral Medicine
dc.titleLong-term response to vasoactive treatment in a case of kyphoscoliosis-associated pulmonary hypertensionen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Long_Term_Response_to_Vasoactive_Treatment.pdf
Size:
1.14 MB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure